Open-label pilot study of senolytics for mild cognitive impairment and Alzheimer's disease
ALSENLITE was an open-label pilot study evaluating the safety and feasibility of dasatinib and quercetin (senolytics) in subjects with mild cognitive impairment or Alzheimer's disease. The abstract reports the study design and objective but does not report results, sample size, or effect sizes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 17, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- Subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease
- Primary outcome
- Safety and feasibility
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Jul 17, 2026
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.